Calidi Biotherapeutics, Inc. (CLDI) - Form 8-K Summary
Business Context and Reporting Period
Calidi Biotherapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on May 14, 2026. The filing announces financial results for the first quarter ended March 31, 2026, and other corporate developments via a press release incorporated as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover document and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing states that detailed financial results are contained in the referenced press release (Exhibit 99.1).
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that the Company issued a press release announcing Q1 2026 results and corporate developments.
Guidance, Outlook, and Risks
Specific guidance, management commentary, risks, contingencies, or unusual items are not detailed in the 8-K text itself. The document notes that the information is furnished under Item 2.02 and Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 14, 2026) for actual Q1 2026 financial figures.
- Verify the specific "corporate developments" mentioned in the press release.
- Confirm the Company's status as an emerging growth company and any related accounting election impacts.
- Check for any subsequent filings that may incorporate the press release details by reference.